FR3110393B1 - Compose et composition pour induire une neuroprotection - Google Patents

Compose et composition pour induire une neuroprotection Download PDF

Info

Publication number
FR3110393B1
FR3110393B1 FR2005138A FR2005138A FR3110393B1 FR 3110393 B1 FR3110393 B1 FR 3110393B1 FR 2005138 A FR2005138 A FR 2005138A FR 2005138 A FR2005138 A FR 2005138A FR 3110393 B1 FR3110393 B1 FR 3110393B1
Authority
FR
France
Prior art keywords
compound
composition
inducing neuroprotection
neuroprotection
inducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2005138A
Other languages
English (en)
French (fr)
Other versions
FR3110393A1 (fr
Inventor
Gilles Rubinstenn
Tangui Maurice
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Montpellier
Ecole Pratique des Hautes Etudes SAS
Rest Therapeutics SAS
Original Assignee
Grn Consulting
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73013493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR3110393(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grn Consulting filed Critical Grn Consulting
Priority to FR2005138A priority Critical patent/FR3110393B1/fr
Priority to CN202180060125.1A priority patent/CN116981449A/zh
Priority to US17/924,420 priority patent/US12611387B2/en
Priority to PCT/FR2021/050929 priority patent/WO2021234324A1/fr
Priority to JP2022571216A priority patent/JP2023531869A/ja
Priority to ES21734182T priority patent/ES2970378T3/es
Priority to EP21734182.5A priority patent/EP4142703B8/fr
Priority to CA3178633A priority patent/CA3178633A1/fr
Priority to KR1020227044712A priority patent/KR20230013116A/ko
Publication of FR3110393A1 publication Critical patent/FR3110393A1/fr
Publication of FR3110393B1 publication Critical patent/FR3110393B1/fr
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
FR2005138A 2020-05-20 2020-05-20 Compose et composition pour induire une neuroprotection Active FR3110393B1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR2005138A FR3110393B1 (fr) 2020-05-20 2020-05-20 Compose et composition pour induire une neuroprotection
EP21734182.5A EP4142703B8 (fr) 2020-05-20 2021-05-20 Composé et composition pour induire une neuroprotection
US17/924,420 US12611387B2 (en) 2020-05-20 2021-05-20 Compound and composition for inducing neuroprotection
PCT/FR2021/050929 WO2021234324A1 (fr) 2020-05-20 2021-05-20 Compose et composition pour induire une neuroprotection
JP2022571216A JP2023531869A (ja) 2020-05-20 2021-05-20 神経保護を誘導するための化合物及び組成物
ES21734182T ES2970378T3 (es) 2020-05-20 2021-05-20 Compuesto y composición para inducir la neuroprotección
CN202180060125.1A CN116981449A (zh) 2020-05-20 2021-05-20 用于引起神经保护的化合物和组合物
CA3178633A CA3178633A1 (fr) 2020-05-20 2021-05-20 Compose et composition pour induire une neuroprotection
KR1020227044712A KR20230013116A (ko) 2020-05-20 2021-05-20 신경보호 유도용 화합물 및 조성물

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2005138 2020-05-20
FR2005138A FR3110393B1 (fr) 2020-05-20 2020-05-20 Compose et composition pour induire une neuroprotection

Publications (2)

Publication Number Publication Date
FR3110393A1 FR3110393A1 (fr) 2021-11-26
FR3110393B1 true FR3110393B1 (fr) 2022-05-06

Family

ID=73013493

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2005138A Active FR3110393B1 (fr) 2020-05-20 2020-05-20 Compose et composition pour induire une neuroprotection

Country Status (9)

Country Link
US (1) US12611387B2 (https=)
EP (1) EP4142703B8 (https=)
JP (1) JP2023531869A (https=)
KR (1) KR20230013116A (https=)
CN (1) CN116981449A (https=)
CA (1) CA3178633A1 (https=)
ES (1) ES2970378T3 (https=)
FR (1) FR3110393B1 (https=)
WO (1) WO2021234324A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3149773B1 (fr) 2023-06-19 2026-04-17 Rest Therapeutics Nouvelles combinaisons synergiques a base de fenm
WO2026003229A1 (fr) 2024-06-26 2026-01-02 Rest Therapeutics Derives de fluoroethylnormemantine pour leur utilisation en tant que medicament
FR3163834A1 (fr) 2024-06-26 2026-01-02 Rest Therapeutics Derives de fluoroethylnormemantine
FR3163835A1 (fr) 2024-06-26 2026-01-02 Rest Therapeutics Derives de fluoroethylnormemantine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200418446A (en) * 2002-10-24 2004-10-01 Merz Pharma Gmbh & Co Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
MX2007004491A (es) * 2004-10-15 2007-08-08 Johnson & Johnson Compuestos de carbamato para utilizar en el tratamiento de padecimientos neurodegenerativos.
US20090118376A1 (en) * 2007-11-02 2009-05-07 Ru-Band Lu Memantine Protects Inflammation-Related Degeneration of Dopamine Neurons Through Inhibition of Over-Activated Microglia and Release of Neurotrophic Factors from Astroglia
FR2935611B1 (fr) 2008-09-10 2010-10-15 Commissariat Energie Atomique Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
US20120115943A1 (en) * 2008-10-01 2012-05-10 National Taiwan University Composition and method for neuroprotection against excitotoxic injury
EP2586436A1 (en) * 2011-10-31 2013-05-01 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor
FR3006193B1 (fr) 2013-05-29 2015-06-19 Holis Technologies Nouveaux composes chimiques derives de la memantine et susceptibles de se fixer sur les recepteurs de n-methyl-d-aspartate (nmda)
FR3050732B1 (fr) 2016-05-02 2019-06-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouveaux derives de phosphinolactones et leurs utilisations pharmaceutiques
FR3075038B1 (fr) 2017-12-15 2020-03-06 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete
EP3968977A4 (en) * 2019-05-15 2023-01-11 The Trustees of Columbia University in the City of New York COMPOSITIONS AND METHODS AGAINST STRESS-INDUCED MOOD DISORDERS AND THEIR ASSOCIATED SYMPTOMS

Also Published As

Publication number Publication date
ES2970378T3 (es) 2024-05-28
FR3110393A1 (fr) 2021-11-26
CN116981449A (zh) 2023-10-31
US20230270695A1 (en) 2023-08-31
US12611387B2 (en) 2026-04-28
KR20230013116A (ko) 2023-01-26
EP4142703B1 (fr) 2023-10-18
JP2023531869A (ja) 2023-07-26
EP4142703B8 (fr) 2023-11-22
EP4142703C0 (fr) 2023-10-18
CA3178633A1 (fr) 2021-11-25
WO2021234324A1 (fr) 2021-11-25
EP4142703A1 (fr) 2023-03-08

Similar Documents

Publication Publication Date Title
FR3110393B1 (fr) Compose et composition pour induire une neuroprotection
MA54229B1 (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
MA31504B1 (fr) Acides benzoylamino-indan-2-carboxyliques substitues et composes apparentes
CR20200376A (es) Inhibidores de cd73
PH12020551304A1 (en) Novel crystalline forms
MX2020014098A (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington.
MX2020013817A (es) Compuestos de naftiridinona sustituidos utiles como activadores de celulas t.
WO2019035864A8 (en) PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF BLOOD DISORDERS
MX2019015580A (es) Metodos para tratar la enfermedad de huntington.
MA58170B1 (fr) Dérivés carboxy avec des proprietes anti-inflammatoires
MA54386B1 (fr) Modulateurs de trex1
DE602004012858D1 (de) 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MX2025015186A (es) Inhibidores de pi3k y uso de estos
PH12020551580A1 (en) Piperidine compounds as covalent menin inhibitor-0s
IL173029A0 (en) Imaging agents
TN2014000243A1 (fr) Benzopyrannes nouveaux, compositions les contenant et leurs utilisations
MA33767B1 (fr) Nouvelle utilisation anticancéreuse du cabazitaxel
MA58993A1 (fr) Antagoniste du récepteur crf1 pour le traitement de l'hyperplasie surrénale congénitale
MA38826B1 (fr) Nouveaux dérivés de triazolo[4,5-d]pyrimidine
MX2023014630A (es) Activadores de dimetoxifenilalquilamina de receptores de serotonina.
BR112017016428A2 (pt) ?composto ou sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto ou sal farmaceuticamente aceitável, e, método para tratamento de um distúrbio hiperproliferativo maligno, de uma condição metabólica associada à obesidade, de um distúrbio autoimune ou de um distúrbio inflamatório?
MA39315A1 (fr) Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique
MA30704B1 (fr) Compositions therapeutiques
PH12021550374A1 (en) Small molecule menin inhibitors

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20211126

PLFP Fee payment

Year of fee payment: 3

TQ Partial transmission of property

Owner name: ECOLE PRATIQUE DES HAUTES ETUDES, FR

Effective date: 20220531

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERC, FR

Effective date: 20220531

Owner name: UNIVERSITE DE MONTPELLIER, FR

Effective date: 20220531

Owner name: REST THERAPEUTICS, FR

Effective date: 20220531

PLFP Fee payment

Year of fee payment: 4

CA Change of address

Effective date: 20231214

PLFP Fee payment

Year of fee payment: 5

CL Concession to grant licences

Name of requester: AXLR, SATT OCCITANIE MEDITERRANEE, FR

Effective date: 20240530

PLFP Fee payment

Year of fee payment: 6